特异于严重急性呼吸系统综合征冠状病毒2型S蛋白受体结合结构域的C6D7-RBD人单克隆抗体的表征。

IF 2 4区生物学 Q4 CELL BIOLOGY

Acta Naturae Pub Date : 2023-01-01 DOI:10.32607/actanaturae.11849

Ya O Romanenko, M V Silkina, A S Kartseva, M A Marin, M A Shkuratova, M A Makarova, A K Ryabko, D A Konyshkova, N A Zeninskaya, A E Khlyntseva, I G Shemyakin, V V Firstova

{"title":"特异于严重急性呼吸系统综合征冠状病毒2型S蛋白受体结合结构域的C6D7-RBD人单克隆抗体的表征。","authors":"Ya O Romanenko, M V Silkina, A S Kartseva, M A Marin, M A Shkuratova, M A Makarova, A K Ryabko, D A Konyshkova, N A Zeninskaya, A E Khlyntseva, I G Shemyakin, V V Firstova","doi":"10.32607/actanaturae.11849","DOIUrl":null,"url":null,"abstract":"The new coronavirus infection COVID-19 is an acute viral disease that affects primarily the upper respiratory tract. The etiological agent of COVID-19 is the SARS-CoV-2 RNA virus (Coronaviridae family, Betacoronavirus genus, Sarbecovirus subgenus). We have developed a high-affinity human monoclonal antibody, called C6D7-RBD, which is specific to the S protein receptor-binding domain (RBD) from the SARS-CoV-2 Wuhan-Hu-1 strain and exhibits virus-neutralizing activity in a test with recombinant antigens: angiotensin-converting enzyme 2 (ACE2) and RBD.","PeriodicalId":6989,"journal":{"name":"Acta Naturae","volume":"15 1","pages":"81-86"},"PeriodicalIF":2.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154778/pdf/","citationCount":"0","resultStr":"{\"title\":\"Characterization of the C6D7-RBD Human Monoclonal Antibody Specific to the SARS-CoV-2 S Protein Receptor-Binding Domain.\",\"authors\":\"Ya O Romanenko, M V Silkina, A S Kartseva, M A Marin, M A Shkuratova, M A Makarova, A K Ryabko, D A Konyshkova, N A Zeninskaya, A E Khlyntseva, I G Shemyakin, V V Firstova\",\"doi\":\"10.32607/actanaturae.11849\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The new coronavirus infection COVID-19 is an acute viral disease that affects primarily the upper respiratory tract. The etiological agent of COVID-19 is the SARS-CoV-2 RNA virus (Coronaviridae family, Betacoronavirus genus, Sarbecovirus subgenus). We have developed a high-affinity human monoclonal antibody, called C6D7-RBD, which is specific to the S protein receptor-binding domain (RBD) from the SARS-CoV-2 Wuhan-Hu-1 strain and exhibits virus-neutralizing activity in a test with recombinant antigens: angiotensin-converting enzyme 2 (ACE2) and RBD.\",\"PeriodicalId\":6989,\"journal\":{\"name\":\"Acta Naturae\",\"volume\":\"15 1\",\"pages\":\"81-86\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154778/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Naturae\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.32607/actanaturae.11849\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Naturae","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.32607/actanaturae.11849","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

新型冠状病毒感染新冠肺炎是一种主要影响上呼吸道的急性病毒性疾病。新冠肺炎的病原体是SARS-CoV-2 RNA病毒（冠状病毒科，Betacoronavirus属，Sarbecovirus亚属）。我们开发了一种高亲和力的人单克隆抗体，称为C6D7-RBD，它对严重急性呼吸系统综合征冠状病毒2型武汉胡1株的S蛋白受体结合域（RBD）具有特异性，并在用重组抗原血管紧张素转化酶2（ACE2）和RBD进行的测试中显示出病毒中和活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Characterization of the C6D7-RBD Human Monoclonal Antibody Specific to the SARS-CoV-2 S Protein Receptor-Binding Domain.

查看原文本刊更多论文

Characterization of the C6D7-RBD Human Monoclonal Antibody Specific to the SARS-CoV-2 S Protein Receptor-Binding Domain.

The new coronavirus infection COVID-19 is an acute viral disease that affects primarily the upper respiratory tract. The etiological agent of COVID-19 is the SARS-CoV-2 RNA virus (Coronaviridae family, Betacoronavirus genus, Sarbecovirus subgenus). We have developed a high-affinity human monoclonal antibody, called C6D7-RBD, which is specific to the S protein receptor-binding domain (RBD) from the SARS-CoV-2 Wuhan-Hu-1 strain and exhibits virus-neutralizing activity in a test with recombinant antigens: angiotensin-converting enzyme 2 (ACE2) and RBD.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Acta Naturae 农林科学-林学

CiteScore

3.50

自引率

5.00%

发文量

审稿时长

>12 weeks

期刊介绍： Acta Naturae is an international journal on life sciences based in Moscow, Russia. Our goal is to present scientific work and discovery in molecular biology, biochemistry, biomedical disciplines and biotechnology. These fields represent the most important priorities for the research and engineering development both in Russia and worldwide. Acta Naturae is also a periodical for those who are curious in various aspects of biotechnological business, innovations in pharmaceutical areas, intellectual property protection and social consequences of scientific progress. The journal publishes analytical industrial surveys focused on the development of different spheres of modern life science and technology. Being a radically new and totally unique journal in Russia, Acta Naturae is useful to both representatives of fundamental research and experts in applied sciences.